Arthritis

Arthritis examined, serum cartilage oligomeric matrix protein clarified

Published in Clinical Trials Week, September 5th, 2005

A study from Poland has documented serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) and knee osteoarthritis (OA).

"COMP is a noncollagenous protein, a glycoprotein, the function of which is to bind to type II collagen fibers and stabilize the collagen fiber network in the articular cartilage. In the serum of the normal population the COMP level is 5 mcg/ml.

"An increased level of COMP in the synovial fluid was described in the early stage of RA, whereas in advanced stages of RA, the level of COMP decreased. In this study we assessed the serum COMP level in patients with RA and knee OA and found a correlation between the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2005-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry